Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:12 PM
Ignite Modification Date:
2025-12-24 @ 5:12 PM
NCT ID:
NCT05962450
Eligibility Criteria:
Inclusion Criteria:
* 18-75 years of age.
* Barcelona Clinic Liver Cancer（BCLC） C stage hepatocellular carcinoma (HCC) confirmed by CT, MRI, and/or histopathology.
* Progressed after receiving anti-angiogenic targeted drugs combined with PD-1 monoclonal antibody.
* Life expectancy of at least 12 weeks.
* Child-Pugh A/B.
* Voluntary signing of informed consent.
Exclusion Criteria:
* History of severe hypertension or cardiac disease.
* known central nervous system (CNS) tumor or combined with other malignant disorders.
* Uncontrolled immune system or infectious disease.
* Known history of the human immunodeficiency virus (HIV) or syphilis infection.
* History of stem cell transplant or organ allograft.
* History of allergy to immunotherapy or related drugs.
* Bilirubin is twice times the upper limit of normal.
* Glomerular filtration rate （GFR）\< 60ml/min.
* Serious complications include moderate or severe infective pleural and peritoneal effusion, pericardial effusion, upper gastrointestinal bleeding, hepatic encephalopathy.
* Pregnancy or lactation.
* History of severe allergy to any monoclonal antibody or anti-angiogenic targeted drug.
* Deemed not suitable for cellular immunotherapy by the investigators.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT05962450
Study Brief:
Protocol Section:
NCT05962450